Company Overview
Company Type: Public Company
Website: www.abcellera.com
Number of Employees: 590
Ticker: ABCL (NasdaqGS)
Year Founded: 2012


Business Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
199.4
Market Capitalization
1,760.9
TEV/Total Revenue
3.9x
EBITDA
(118.5)
Total Enterprise Value
783.3
TEV/EBITDA
NM
EBIT
(148.2)
Cash & ST Invst.
1,093.1
P/Diluted EPS Before Extra
NM
Net Income
(101.5)
Total Debt
115.4
Price/Tang BV
1.3x
Capital Expenditure
(92.1)
Total Assets
2,111.7
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.17)
(0.18)
(0.67)
(0.76)
(0.76)
Revenue (mm)
15.55
16.51
61.91
90.01
76.04
EBITDA (mm)
-
-
(221.89)
(232.64)
(227.27)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
12.59x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Buy (1.13)
Target Price
33.56
Potential Upside
452.68%


Key Professionals
Name
Title
Hansen, Carl L.G.
CEO, President & Chairperson
Booth, Andrew 
Chief Financial Officer
Lecault, Veronique 
COO & Director
Thiessen, Marcie 
Senior Director of Finance & Accounting
Falconer, Ester 
Chief Technology Officer
Hellschlienger, Josephine 
Manager of Investor Relations
Stimart, Tryn T.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Chiu, Tiffany 
Vice President of Communications
Craig, Graham 
Director of Corporate Development
Weirich, Alexandra 
Manager of Marketing & Communications
Webster, Caitlin 
Senior Manager of People & Culture
Aubuchon, Neil 
Chief Commercial Officer

Key Board Members
Name
Title
Hansen, Carl L.G.
CEO, President & Chairperson
Lecault, Veronique 
COO & Director
Hayden, Michael R.
Independent Lead Director
Montalbano, John Salvatore
Independent Non-Employee Director
Thiel, Peter Andreas
Independent Non-Employee Director
Lo, Wen-Chaun 
Independent Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
2215 Yukon Street | Vancouver, BC | V5Y 0A1 | Canada

Current and Pending Investors
Catalio Capital Management, LP, Data Collective (John Hamer), Eli Lilly and Company (NYSE:LLY), Genworks 2 Consulting Inc, Innovation, Science And Economic Development Canada, Northview LifeSciences (Douglas Janzen), OrbiMed Advisors LLC, Presight Capital, The Founders Fund, LLC, University of Minnesota, Endowment Arm, Vancouver (City of), Viking Global Investors LP

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 6.07
Market Cap (mm)
1,757.0
Open
 6.09
Shares Out. (mm)
289.4
Previous Close
 6.07
Float %
67.3%
Change on Day
(0.01)
Shares Sold Short (mm)
25.3
Change % on Day
(0.2)%
Dividend Yield %
-
Day High/Low
 6.20/ 5.96
Diluted EPS Excl. Extra Items
(0.36)
52 wk High/Low
 20.57/ 5.95
P/Diluted EPS Before Extra
NM
Volume (mm)
1.26
Avg 3M Dly Vlm (mm)
1.95
Beta 5Y
0.09


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
NasdaqGS:ABCL - Common Stock


Index Membership
S&P Americas Under USD3 Billion Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Under USD2 Billion Index;S&P Americas BMI Growth Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Canada SmallCap Index;S&P Canada SmallCap Growth Index;S&P Canada SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Between USD500 Million and USD2.5 Billion Index;S&P Canada BMI Growth Index;S&P Americas SmallCap Growth Index;S&P Canada Under USD2 Billion Index;S&P Americas Between USD1 Billion and USD5 Billion Index;S&P Americas SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia Between USD1 Billion and USD5 Billion Index;S&P DM Ex-Australia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada SmallCap Health Care (Sector) Index;S&P Canada Under USD3 Billion Index;S&P Canada BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Europe Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed Between USD1 Billion and USD5 Billion Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD3 Billion Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Switzerland Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Switzerland Under USD3 Billion Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD2 Billion Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan Under USD2 Billion Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland Under USD2 Billion Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Eurozone Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific Under USD3 Billion Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Growth Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Index;S&P Developed Ex-U.S. & Japan SmallCap Health Care (Sector) Index;S&P Developed Ex-Europe Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD3 Billion Index;S&P Developed Ex-U.S. & Japan Under USD2 Billion Index;S&P Developed Ex-U.S. & U.K. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Index;S&P Developed Ex-U.S. & U.K. BMI Growth Index;S&P Developed Ex-U.S. & U.K. SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. Under USD3 Billion Index;S&P Developed Ex-U.S. BMI Growth Health Care (Sector) Index;S&P Developed Under USD3 Billion Index;S&P Developed Ex-U.S. SmallCap Health Care (Sector) Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P DM Ex-Eurozone SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P DM Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada Between USD500 Million and USD2.5 Billion Index;S&P Canada BMI Growth Health Care (Sector) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.S. & Japan Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed Between USD500 Million and USD2.5 Billion Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Under USD2 Billion Index;S&P Developed Ex-Eurozone Under USD3 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Index;S&P Developed Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. BMI Growth Index;S&P Developed Ex-U.S. & U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Growth Health Care (Sector) Index;S&P DM Ex-U.S. & U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & U.K. SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Under USD2 Billion Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Growth Index;S&P Global Between USD1 Billion and USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Under USD2 Billion Index;S&P Developed Ex-Europe Under USD3 Billion Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-U.K. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Under USD2 Billion Index;S&P Developed Ex-U.K. Under USD3 Billion Index;S&P Canada Between USD1 Billion and USD5 Billion Index;S&P Canada BMI Index;S&P Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan SmallCap Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Global Ex-Japan Under USD2 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Growth Index;S&P Developed Ex-Japan Under USD3 Billion Index;S&P Developed Ex-U.K. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.K. BMI Index;S&P Global Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Global BMI Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global Ex-U.S. SmallCap Growth Index;S&P Global SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Index;S&P Developed Ex-U.S. Under USD2 Billion Index;S&P Developed Under USD2 Billion Index;S&P Global Ex-U.S. SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. Under USD3 Billion Index;S&P Global Under USD2 Billion Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America SmallCap Index;S&P North America SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. SmallCap Index;S&P Global Ex-U.S. Under USD2 Billion Index;S&P North America BMI Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Pan Asia Under USD2 Billion Index;S&P Global Ex-Pan Asia Under USD3 Billion Index;S&P Global Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-U.S. BMI Index;S&P Global Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan Under USD3 Billion Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America Under USD2 Billion Index;S&P North America Under USD3 Billion Index;S&P Global BMI Growth Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P Canada SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Australia Under USD2 Billion Index;S&P DM Ex-Europe SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed Ex-U.S. & Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P Global Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P North America Between USD1 Billion and USD5 Billion Index;S&P North America Between USD500 Million and USD2.5 Billion Index;S&P North America SmallCap Growth Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P DM Ex-Israel SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel BMI Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Israel BMI Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Israel Under USD2 Billion Index;S&P Developed Ex-Israel Under USD3 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Americas Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Canada Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Australia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Europe Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Eurozone Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Israel Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Switzerland Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. & Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Pan Asia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P North America Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed BMI Ex-U.S. & Korea Index;S&P DM Ex. Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Australia SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Israel SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-U.S. & Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P Developed Ex-U.S. & U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Canada SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Europe SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.S. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia & New Zealand Between USD1 Billion and USD5 Billion;S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-U.S. & Korea SmallCap;S&P Developed Ex-Korea SmallCap;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. SmallCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
TetraGenetics, Inc.
TetraGenetics, Inc., a biotechnology company, develops therapeutic proteins and vaccines for the pharmaceutical industry. The company offers recombinant human ion channel protein using its proprietary TetraExpress system. Its products include IchVax, which is a recombinant subunit vaccine for the prevention of white spot disease in freshwater fish. TetraGenetics, Inc. has a strategic research and development collaboration with Imbrium Therapeutics L.P. TetraGenetics, Inc. was incorporated in 2004 and is based in Arlington, Massachusetts. TetraGenetics, Inc. operates as a subsidiary of AbCellera Biologics Inc.

United States and Canada
Biotechnology
-
-
-
Trianni, Inc.
Trianni, Inc. develops and provides a humanized monoclonal antibody discovery platform. It offers The Trianni Mouse, an antibody research platform that provides human antibody repertoire for the facile isolation of monoclonal antibodies. The company was founded in 2010 and is based in San Francisco, California. Trianni, Inc. operates as a subsidiary of AbCellera Biologics Inc.

United States and Canada
Biotechnology
-
-
-
Lineage Biosciences, Inc.
Lineage Biosciences, Inc. provides a technology for the profiling of antibody responses using the sequencing of immunoglobulin genes. The company was incorporated in 2014 and is based in Palo Alto, California. As of March 31, 2017, Lineage Biosciences, Inc. operates as a subsidiary of AbCellera Biologics Inc..

United States and Canada
Biotechnology
-
-
-
AbCellera Australia Pty Ltd.
AbCellera Australia Pty Ltd. operates as a subsidiary of AbCellera Biologics Inc. 

Asia / Pacific
-
-
-
-
AbCellera Biologics UK Ltd.
AbCellera Biologics UK Ltd. operates as a subsidiary of AbCellera Biologics Inc.

Europe
-
-
-
-
AbCellera Boston, Inc.
AbCellera Boston, Inc. operates as a subsidiary of AbCellera Biologics Inc. 

United States and Canada
-
-
-
-
AbCellera Properties Columbia Inc.
AbCellera Properties Columbia Inc. operates as a subsidiary of AbCellera Biologics Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-21-2023
-
Shelf Registration
Target
AbCellera Biologics Inc. (NasdaqGS:ABCL)


137.55
Feb-25-2022
-
Shelf Registration
Target
AbCellera Biologics Inc. (NasdaqGS:ABCL)


119.72
Feb-25-2022
-
Shelf Registration
Target
AbCellera Biologics Inc. (NasdaqGS:ABCL)


-
Sep-13-2021
Sep-10-2021
Merger/Acquisition
Buyer
TetraGenetics, Inc.
AbCellera Biologics Inc. (NasdaqGS:ABCL)

62.50
Jun-10-2021
Jun-21-2021
Shelf Registration
Target
AbCellera Biologics Inc. (NasdaqGS:ABCL)

SB Northstar LP,Genworks 2 Consulting Inc
286.08
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-20-2023
Client Announcements
AbCellera Biologics Inc. Expands Multi-Target Antibody Discovery Collaboration with Regeneron
Sep-13-2023
Strategic Alliances
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
Aug-03-2023
Earnings Calls
AbCellera Biologics Inc., Q2 2023 Earnings Call, Aug 03, 2023
Jul-24-2023
Lawsuits & Legal Issues
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing
Jun-23-2023
Index Constituent Drops
AbCellera Biologics Inc.(NasdaqGS:ABCL) dropped from Russell 2500 Growth Index

Competitors
10x Genomics, Inc. (NasdaqGS:TXG), AbbVie Inc. (NYSE:ABBV), Ablexis, LLC, Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Adimab, LLC, Aldevron, LLC, Alloy Therapeutics, Inc., Atreca, Inc. (NasdaqGS:BCEL), Certara, Inc. (NasdaqGS:CERT), Charles River Laboratories International, Inc. (NYSE:CRL), Crescendo Biologics Limited, Curia Global, Inc., Distributed Bio, Inc., Evotec SE (XTRA:EVT), Genmab A/S (CPSE:GMAB), Genovac AG, GenScript Biotech Corporation, Harbour Antibodies BV, HiFiBiO SAS, HiFiBiO, Inc., IONTAS Limited, Kymab Limited, Leveragen, Inc., Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), Merus N.V. (NasdaqGM:MRUS), OmniAb, Inc. (NasdaqGM:OABI), PhenomeX Inc., Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), RenBio, Inc., Schrödinger, Inc. (NasdaqGS:SDGR), Sphere Fluidics Limited, Twist Bioscience Corporation (NasdaqGS:TWST), WuXi Biologics (Cayman) Inc. (SEHK:2269), Zymeworks Inc. (NasdaqGS:ZYME)

M&A Advisors
Borden Ladner Gervais LLP, McCarthy Tétrault LLP


Advisors
Most Recent Auditor
KPMG Limited
M&A Advisors
Borden Ladner Gervais LLP, McCarthy Tétrault LLP
Private Placement Advisors
Dorsey & Whitney LLP
Public Offering Advisors
Blake, Cassels & Graydon LLP, Goodwin Procter LLP, KPMG LLP


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

04:22 AM
ABCL
Abcellera Biologics Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 02:42 AM
ABCL
ValuEngine Rating and Forecast Report for ABCL
Reports
11
CFRA Equity Research

Oct 01, 2023 08:22 AM
ABCL
AbCellera Biologics Inc.
Reports
9
New Constructs, LLC

Sep 29, 2023 08:06 PM
ABCL
ABCL: Forensic Stock Earnings & Valuation
Reports
6
GlobalData

Sep 26, 2023 05:10 AM
ABCL
AbCellera Biologics Inc (ABCL.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
132
GlobalData

Sep 15, 2023 07:44 AM
ABCL
AbCellera Biologics Inc (ABCL.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
32
Quant IP GmbH
Quant IP Research Team
Sep 13, 2023 06:00 PM
ABCL
Quant IP Competitive Technology Report AbCellera-Biologics-Inc 2023-09-01
Reports
31
GlobalData

Sep 13, 2023 04:01 AM
ABCL
AbCellera Biologics Inc (ABCL.NASD) - Financial Analysis Review
Reports
240
Marktfeld
Paraskevopoulos, Michail
Sep 09, 2023 06:40 AM
ABCL
Abcellera Biologics Inc (ABCL.US): Investor Targeting - September 2023
Reports
14
S&P Global Compustat

Sep 07, 2023 04:20 AM
ABCL
Abcellera Biologics Inc 2023_09_07
Reports
15


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Hansen Ph.D., Carl L.G.

56,629,868

19.57

341.1

Aug-24-2023


Baillie Gifford & Co.

26,364,751

9.11

158.8

Jun-30-2023


Baker Bros. Advisors LP

16,450,180

5.69

99.1

Jun-30-2023


Voya Investment Management LLC

10,624,185

3.67

64.0

Jun-30-2023


Thiel, Peter Andreas

10,179,880

3.52

61.3

Apr-24-2023


Lecault Ph.D., Veronique 

9,530,340

3.29

57.4

Sep-12-2023


Capital Research and Management Company

8,420,493

2.91

50.7

Jun-30-2023


Allianz Global Investors U.S. LLC

4,724,100

1.63

28.5

Sep-26-2022


Credit Suisse Asset Management (Switzerland)

4,569,943

1.58

27.5

Jun-30-2023


OrbiMed Advisors LLC

4,180,768

1.44

25.2

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Baillie Gifford & Co.
26,364,751
6,535,100
Baker Bros. Advisors LP
16,450,180
6,000,000
ArrowMark Colorado Holdings, LLC
4,105,095
4,105,095
Millennium Management LLC
3,267,618
2,060,920
Prosight Management, LP
2,550,000
1,796,472

Top Sellers
Sellers
Common Stock Equivalent Held
Change
BlackRock, Inc.
3,451,398
(10,242,897)
Harvard Management Company, Inc.
0
(4,105,095)
State Street Global Advisors, Inc.
252,440
(3,137,365)
Geode Capital Management, LLC
251,674
(1,923,874)
Northern Trust Global Investments
100,268
(1,585,189)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-15
AbCellera Biologics Enters into Co-Development Agreement with Incyte
Marketline - Deals
Sep-14
AbCellera Biologics Enters into Co-Development Agreement with Incyte
Marketline - Deals
Sep-14
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
ENP Newswire
Sep-13
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
Business Wire


Company Coverage
This company is not on any Coverage List.

Products
AI-Powered Drug Discovery Platform, Bamlanivimab, Bebtelovimab, Etesevimab, IVX-01 (Future), NBL-012 (Future), NBL-015/FL-301 (Future), NBL-020 (Future), TAK-920/DNL919 (Future), Trianni


Upcoming Events
Date/Time
Type
Oct-24-2023
Conferences
Oct-24-2023 3:45 PM (EDT)
Company Conference Presentations
Nov-03-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-03-2023
Jun-30-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
10-Q
23 MB
Aug-03-2023
Aug-03-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
8-K (2.02, 7.01, 9.01)
2 MB
Jun-20-2023
Jun-15-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
8-K (5.07)
154 KB
May-24-2023
May-24-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
8-K (1.01, 2.03, 8.01, 9.01)
1 MB
May-04-2023
Mar-31-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
10-Q
6 MB
May-04-2023
May-04-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
8-K (2.02, 7.01, 9.01)
4 MB
Apr-28-2023
-
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
DEFA14A
3 MB
Apr-28-2023
-
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
DEF 14A
5 MB
Mar-13-2023
Mar-10-2023
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
8-K (7.01)
165 KB
Feb-21-2023
-
AbCellera Biologics Inc. (NasdaqGS:ABCL)
SEC
S-8
90 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Hayden CM, FRCP(C), FRCPC, FRSC, M.B. ChB., M.D., OBC, Ph, Michael R. (Independent Lead Director)
Sep-22-2023
Common Shares
20,000
134,902
Open Market Acquisition
1.41
Form 4
Lecault Ph.D., Veronique  (COO & Director)
Sep-12-2023
Common Shares
20,000
142,595
Open Market Acquisition
0.21
Form 4
Hansen Ph.D., Carl L.G. (CEO, President & Chairperson)
Aug-24-2023
Common Shares
56,125
208,175
Derivative Exercise and Retained Stock
0.10
Form 4
Hayden CM, FRCP(C), FRCPC, FRSC, M.B. ChB., M.D., OBC, Ph, Michael R. (Independent Lead Director)
Aug-08-2023
Common Shares
30,000
243,154
Open Market Acquisition
2.16
Form 4
Hansen Ph.D., Carl L.G. (CEO, President & Chairperson)
May-26-2023
Common Shares
56,125
208,175
Derivative Exercise and Retained Stock
0.10
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Hansen, Carl L.G.
CEO, President & Chairperson
-
-

Lecault, Veronique 
COO & Director
-
-

Hayden, Michael R.
Independent Lead Director
-
-

Montalbano, John Salvatore
Independent Non-Employee Director
-
-

Thiel, Peter Andreas
Independent Non-Employee Director
-
-

Lo, Wen-Chaun 
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Hansen, Carl L.G.
CEO, President & Chairperson
-
-

Booth, Andrew 
Chief Financial Officer
-
-

Lecault, Veronique 
COO & Director
-
-

Thiessen, Marcie 
Senior Director of Finance & Accounting
-
-

Falconer, Ester 
Chief Technology Officer
-
-

Hellschlienger, Josephine 
Manager of Investor Relations
-
-

Stimart, Tryn T.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
-
-

Chiu, Tiffany 
Vice President of Communications
-
-

Craig, Graham 
Director of Corporate Development
-
-

Weirich, Alexandra 
Manager of Marketing & Communications
-
-

Webster, Caitlin 
Senior Manager of People & Culture
-
-

Aubuchon, Neil 
Chief Commercial Officer
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
